Agios Pharmaceuticals (FRA:8AP) Moat Score: 5/10 (As of Jul. 01, 2026)


FRA:8AP Agios Pharmaceuticals Inc FRA:8AP
46 GF Score
Price €33.20
GF Value €75.15
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Moat Score?

Agios Pharmaceuticals FRA:8AP 46 Moat Score is 5 as of Jul. 01, 2026. GuruFocus rates FRA:8AP with a GF Score™ of 46/100 and a GF Value™ of €75.15 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,400 Biotechnology companies, Agios Pharmaceuticals ranks better than 96.71% on this metric.

Agios Pharmaceuticals has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Agios Pharmaceuticals has Narrow Moat: Agios has a solid narrow moat due to its valuable intellectual property and strong R&D capabilities in the pharmaceutical sector. While it has some pricing power and regulatory barriers, its market share and brand strength are not dominant enough for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Agios Pharmaceuticals might have Narrow Moat - Solid narrow moat.

Agios Pharmaceuticals  (FRA:8AP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Agios Pharmaceuticals Moat Score Related Terms

FRA:8AP vs ABCL, KOD, IMNM: Moat Score Comparison

For the Biotechnology subindustry, Agios Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agios Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Moat Score falls into.


FRA:8AP
46GF Score
Agios Pharmaceuticals Inc FRA:8AP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Agios Pharmaceuticals (FRA:8AP) has a Moat Score of 5 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Agios Pharmaceuticals ranks #46 out of 1400 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Agios Pharmaceuticals' Moat Score too high?
Agios Pharmaceuticals' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Agios Pharmaceuticals' value of 5 is 150% above this industry median. Based on the distribution chart, Agios Pharmaceuticals ranks #46 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Agios Pharmaceuticals has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Moat Score compare to ABCL and KOD?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #46 out of 1400 companies for Moat Score. This places Agios Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Agios Pharmaceuticals' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agios Pharmaceuticals's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agios Pharmaceuticals's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (FRA:8AP) is currently considered Possible Value Trap. The stock's GF Value™ is €75.15, compared to a current price of €33.20 — trading 55.8% below its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Agios Pharmaceuticals' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current Moat Score is 5 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €33.20 is trading 55.8% below its estimated GF Value™ of €75.15. GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:8AP:

  • Moat Score: 5
  • GF Value™: €75.15 vs. price of €33.20 (55.8% below fair value)
  • GF Score™: 46/100 with 3 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1400)

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
46GF Score

Get the complete analysis for FRA:8AP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.20
Price
€75.15
GF Value